DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Byetta (Exenatide Injection) - Published Studies

 
 



Byetta Related Published Studies

Well-designed clinical trials related to Byetta (Exenatide Injection)

Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data. [2013]

Exenatide and the treatment of patients with Parkinson's disease. [2013]

Effects of HbA1c and weight reduction on blood pressure in patients with type 2 diabetes mellitus treated with exenatide*. [2012]

Investigation of the haemodynamic effects of exenatide in healthy male subjects. [2012]

Exenatide as a Weight-Loss Therapy in Extreme Pediatric Obesity: A Randomized, Controlled Pilot Study. [2011.11.10]

Exenatide or glimepiride added to metformin on metabolic control and on insulin resistance in type 2 diabetic patients. [2011.09]

[Cost-effectiveness of exenatide versus insulin glargine in Spanish patients with obesity and type 2 diabetes mellitus]. [2011.08]

Effects of a single dose of exenatide on appetite, gut hormones, and glucose homeostasis in adults with Prader-Willi syndrome. [2011.08]

The GLP-1 mimetic exenatide potentiates insulin secretion in healthy cats. [2011.07]

DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide. [2011.06]

Patient-reported outcomes are superior in patients with Type 2 diabetes treated with liraglutide as compared with exenatide, when added to metformin, sulphonylurea or both: results from a randomized, open-label study. [2011.06]

DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. [2011.05]

Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia. [2011.03]

Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus. [2011.02]

Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment. [2011.02]

Exenatide - pharmacokinetics, pharmacodynamics, safety and tolerability in patients >/= 75 years of age with Type 2 diabetes. [2011.02]

Effect of administration time of exenatide on satiety responses, blood glucose, and adverse events in healthy volunteers. [2011.02]

Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. [2011.01.18]

A placebo-controlled trial of exenatide twice-daily added to thiazolidinediones alone or in combination with metformin. [2010.12]

Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. [2010.09]

One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. [2010.09]

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. [2010.08.07]

Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. [2010.08]

Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. [2010.07]

Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. [2010.06.26]

The role of adjunctive exenatide therapy in pediatric type 1 diabetes. [2010.06]

Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. [2010.06]

Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. [2010.06]

Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. [2010.05]

Improvement of postprandial endothelial function after a single dose of exenatide in individuals with impaired glucose tolerance and recent-onset type 2 diabetes. [2010.05]

Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. [2010.05]

Exenatide versus glibenclamide in patients with diabetes. [2010.03]

Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. [2010.01.28]

Effects of exenatide alone and in combination with daclizumab on beta-cell function in long-standing type 1 diabetes. [2009.12]

Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. [2009.12]

Evaluation of exenatide vs. insulin glargine in type 2 diabetes: cost-effectiveness analysis in the German setting. [2009.11]

The effect of exenatide on lisinopril pharmacodynamics and pharmacokinetics in patients with hypertension. [2009.11]

Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland. [2009.08]

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). [2009.07.04]

Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. [2009.06]

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. [2009.05]

Pharmacology and tolerability of a single dose of exenatide in adolescent patients with type 2 diabetes mellitus being treated with metformin: a randomized, placebo-controlled, single-blind, dose-escalation, crossover study. [2009.04]

One-Year Treatment With Exenatide Improves Beta-Cell Function, Compared To Insulin Glargine, In Metformin Treated Type 2 Diabetes Patients: A Randomized, Controlled Trial. [2009.02.05]

Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. [2009.01]

Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes. [2009]

Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. [2009]

Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. [2008.11.29]

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. [2008.10.04]

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. [2008.08]

Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis. [2008.03]

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. [2008.01]

Effect of renal impairment on the pharmacokinetics of exenatide. [2007.09]

Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. [2007.06]

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. [2007.04.03]

Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes. [2007.03]

Exenatide effects on statin pharmacokinetics and lipid response. [2007.02]

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. [2007.01]

Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea. [2006.12]

Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. [2006.11]

Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. [2006.10.11]

Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. [2006.07]

Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. [2006.07]

Exenatide: effect of injection time on postprandial glucose in patients with Type 2 diabetes. [2006.03]

Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. [2005.11]

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. [2005.10.18]

Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes. [2005.10]

Exenatide improves glycemic control and reduces body weight in subjects with type 2 diabetes: a dose-ranging study. [2005.06]

Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. [2005.05]

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. [2005.05]

Pharmacokinetics of an oral drug (acetaminophen) administered at various times in relation to subcutaneous injection of exenatide (exendin-4) in healthy subjects. [2005.05]

A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic exendin-4). [2005.02]

Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. [2005.01.15]

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. [2004.11]

Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. [2004.09]

Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. [2004.09]

Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. [2003.08]

Well-designed clinical trials possibly related to Byetta (Exenatide Injection)

Pharmacokinetic properties and effects of PT302 after repeated oral glucose loading tests in a dose-escalating study. [2014]

Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. [2011.02]

Impact of postprandial and fasting glucose concentrations on HbA1c in patients with type 2 diabetes. [2010.11]

Contemporary management of patients with Type 2 diabetes. [2010.06]

Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. [2009.10]

Efficacy and safety of incretinbased therapies: clinical trial data. [2009.09]

Other research related to Byetta (Exenatide Injection)

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. [2013]

Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. [2013]

Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus. [2013]

Addition of exenatide or sitagliptin to insulin in new onset type 1 diabetes: a randomized, open label study. [2013]

Once weekly exenatide: efficacy, tolerability and place in therapy. [2013]

Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. [2013]

Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy. [2012]

Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications. [2012]

Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide. [2012]

Baseline factors associated with glycemic control and weight loss when exenatide twice daily is added to optimized insulin glargine in patients with type 2 diabetes. [2012]

Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes. [2011.10.31]

Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis. [2011]

Sitagliptin or exenatide once weekly for type 2 diabetes: comparison of the clinical trials. [2011]

Exenatide: a new promising antidiabetic agent. [2010.01]

The use of exenatide in severely burned pediatric patients. [2010]

Effects of Exenatide Alone and in Combination with Daclizumab on Beta Cell Function in Long-Standing Type 1 Diabetes Mellitus. [2009.10.06]

The European Exenatide study of long-term exenatide vs. glimepiride for type 2 diabetes: rationale and patient characteristics. [2009.09.13]

Is liraglutide or exenatide better in type 2 diabetes? [2009.09.10]

Exenatide efficacy and safety: a systematic review. [2009.09]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014